Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Formycon AG's enterprise value is €314.56 Mil.
Formycon AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €18.18 Mil. Therefore, Formycon AG's EV-to-EBITDA for today is 17.31.
The historical rank and industry rank for Formycon AG's EV-to-EBITDA or its related term are showing as below:
CHIX:FYBd'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -457.35 Med: -82.81 Max: 127.76
Current: 17.31
During the past 13 years, the highest EV-to-EBITDA of Formycon AG was 127.76. The lowest was -457.35. And the median was -82.81.
CHIX:FYBd's EV-to-EBITDA is ranked worse than 54.11% of 401
companies
in the Biotechnology industry
Industry Median: 14.49
vs CHIX:FYBd: 17.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Formycon AG's PE Ratio (TTM) for today is calculated as:
Formycon AG's share price for today is €63.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-1.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Formycon AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:FYBD vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Formycon AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Formycon AG's EV-to-EBITDA falls into.
Formycon AG's current Enterprise Value is €314.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Formycon AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €18.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (CHIX:FYBD) has a EV-to-EBITDA of 17.31 as of Aug. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Formycon AG. According to the industry distribution chart, Formycon AG ranks #217 out of 401 companies in the Biotechnology industry, placing it in the top 54.1%.
Is Formycon AG's EV-to-EBITDA too high?
Formycon AG's current EV-to-EBITDA is 17.31. The Biotechnology industry median EV-to-EBITDA is 14.49. Formycon AG's value of 17.31 is 19.5% above this industry median. Based on the distribution chart, Formycon AG ranks #217 out of 401 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Formycon AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #217 out of 401 companies for EV-to-EBITDA. This places Formycon AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.49. Formycon AG's value of 17.31 is 19.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.49, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formycon AG's current EV-to-EBITDA of 17.31 is 19.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Formycon AG. For the Biotechnology industry, the median EV-to-EBITDA is 14.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formycon AG's current EV-to-EBITDA is 17.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current EV-to-EBITDA of 17.31. The stock's GF Value™ is €102.12, compared to a current price of €63.30 — trading 38% below its estimated fair value. The current EV-to-EBITDA is 17.31 and 19.5% above the Biotechnology industry median of 14.49. Formycon AG's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current EV-to-EBITDA is 17.31 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (CHIX:FYBD) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €63.30 is trading 38% below its estimated GF Value™ of €102.12.
Key valuation signals for CHIX:FYBD:
EV-to-EBITDA: 17.31
GF Value™: €102.12 vs. price of €63.30 (38% below fair value)
Industry Position: 19.5% above the Biotechnology median (#217 of 401)
No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
68GF Score
Get the complete analysis for CHIX:FYBD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:FYBD has been successfully added to your 
